You are here

AI-Enabled Test for Kidney Disease Gets Breakthrough Device Designation

FDA Gives Priority Regulatory Review of Diagnostic for Fast-Progressing Kidney Disease

Renalytix AI plc has received an FDA Breakthrough Device Designation for KidneyIntelXTM, its main diagnostic test for kidney disease.

The device is designed to diagnose and improve clinical management of patients with type-2 diabetes with fast-progressing kidney disease. Using machine-learning algorithms, KidneyIntelX will assess the combination of predictive blood-based biomarkers, including sTNFR1, sTNFR2 and KIM1, with electronic health record information, to identify progressive kidney disease.

Globally, kidney disease is recognized as a public health epidemic affecting more than 850 million people, making its early detection and intervention crucial. The annual cost of chronic and end-stage kidney disease to the U.S. health care system is estimated to be $114 billion. Each day, 13 patients die in the U.S. while waiting for a kidney transplant.

Source: Renalytix AI plc, May 2, 2019

Recent Headlines

First New Medication for Seizure Clusters in More Than Two Decades
Novel, Low-cost Device Highly Accurate at Screening Newborn Jaundice
Mode Delivers Antivirals Safely, Cheaply to Remote Regions
First Devices Cleared for Diagnostic Testing Via Throat, Rectum Specimens
Averts Disease Worsening, Reduces Potential for Blindness
Risk May Remain for 6 Months After Treatment
FDA Removes Boxed Warning With Drug’s Fifth Approval
Overeager Use of Recommendations Creates Problems
Artificial Intelligence Enables Platform to Detect Amyloid PET Status